Articlenpj aging2025
Frailty and transitions across cardiometabolic disease states: evidence from multistate models in a 16-year Chinese cohort.
Article in npj aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Characterization of Models for Identifying Physical and Cognitive Frailty in Older Adults With Diabetes: Systematic Review and Meta-Analysis.Journal of medical Internet research · 2026Pooled it
- The association between triglyceride glucose-frailty index and cardiometabolic multimorbidity among Chinese middle-aged and older adults: a national prospective cohort study.Cardiovascular diabetology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Frailty is a prevalent geriatric syndrome, but its role in cardiometabolic disease (CMD) progression remains unclear. We examined whether frailty predicted CMD transitions. We included 22,754 participants aged 50+ from the Guangzhou Biobank Cohort Study without baseline CMD. Frailty was assessed using a 35-item frailty index (FI). Cardiometabolic multimorbidity (CMM) was defined as ≥2 of type 2 diabetes, ischemic heart disease, and stroke. Cox and multistate models estimated associations of frailty with first CMD (FCMD), CMM, and mortality. During a mean follow-up of 16.4 years, 8710 developed FCMD, 2332 progressed to CMM, and 5411 died. After adjustment, multistate analyses showed that frailty accelerated transitions from health to FCMD, from FCMD to CMM, and from CMM to death (HR per 0.1 increment in FI ranging from 1.14 to 1.48). Frailty was independently associated with CMD progression and mortality. Multistate analyses highlight its dynamic role in multimorbidity, supporting routine frailty assessment in cardiometabolic prevention.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.